Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12197476 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2GLAHPGDMAPTKMT2A | |
| SCHEMBL10091362 | 0.97 | SMN1; SMN2 (0.38) | SMN1; SMN2GLAHPGDMAPTKMT2A | |
| SCHEMBL14922631 | 0.94 | SMN1; SMN2 (0.40) | SMN1; SMN2GLAHPGDMAPTKMT2A | |
| SCHEMBL14922394 | 0.94 | SMN1; SMN2 (0.40) | SMN1; SMN2GLAHPGDMAPTKMT2A | |
| SCHEMBL12196524 | 0.93 | SMN1; SMN2 (0.36) | SMN1; SMN2GLAHPGDMAPTKMT2A | |
| SCHEMBL12196535 | 0.93 | SMN1; SMN2 (0.36) | SMN1; SMN2GLAHPGDMAPTKMT2A | |
| SCHEMBL12196509 | 0.92 | SCN9A (0.36) | SMN1; SMN2GLAHPGDKMT2AGAA | |
| SCHEMBL12197468 | 0.92 | SCN9A (0.36) | SMN1; SMN2GLAHPGDKMT2AGAA | |
| SCHEMBL10091365 | 0.90 | HPGD (0.41) | SMN1; SMN2GLAHPGDKMT2AGAA | |
| SCHEMBL14922680 | 0.89 | SMN1; SMN2 (0.36) | SMN1; SMN2GLAHPGDMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435422-B2 | Five-ring compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, CCND3, ZKSCAN2 | SMN1; SMN2 3764/4885GLA 3232/4885HPGD 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.